DIRS.INFO The most relevant business & tech news

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., July 26, 2023. All eyes will be squarely on the July U.S. nonfarm payrolls report, due at 8:30 a.m. ET, with a Reuters poll of economists estimating payrolls increased by 200,000 jobs last month, after having risen 209,000 in June, showing labor market conditions remain tight. "Today's NFP data would be important for setting the market tone for the coming weeks," Jefferies strategist Mohit Kumar said. ET, Dow e-minis were up 10 points, or 0.03%, S&P 500 e-minis were up 8.5 points, or 0.19%, and Nasdaq 100 e-minis were up 44.25 points, or 0.29%.

Persons: Brendan McDermid, Amazon's, nonfarm, Jefferies, Mohit Kumar, Stocks, DraftKings, Shubham Batra, Bansari, Savio D'Souza, Shounak Organizations: New York Stock Exchange, REUTERS, Apple Futures, Dow, Nasdaq, Amazon.com, Microsoft, Labor Department, Fitch, AAA, Dow e, Horizon Therapeutics, Sports, Thomson Locations: New York City, U.S, States, Bengaluru

☆ US FTC seeks additional info on Pfizer's proposed takeover of Seagen
▼ + stars: | 2023-07-15 | by ( ) www.reuters.com time to read: +1 min

[1/2] The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/File Photo/File PhotoJuly 14 (Reuters) - The US Federal Trade Commission (FTC) has sought additional information and documentary material related to Pfizer's (PFE.N) proposed acquisition of Seagen Inc (SGEN.O), Seagen said on Friday. The antitrust agency sent the requests separately to both the companies, a regulatory filing said. Pfizer struck a $43 billion deal in March to acquire Seagen and its targeted cancer therapies, to counter the fall in COVID-related sales and generic competition for some top-selling drugs. The recent scrutiny by the antitrust agency to block Amgen's (AMGN.O) $27.8 billion deal to buy Horizon Therapeutics (HZNP.O) has made investors jittery around the Pfizer-Seagen deal as well.

Persons: Carlo Allegri, Seagen, Khushi, Shailesh Organizations: Pfizer, REUTERS, US Federal Trade Commission, Seagen Inc, Horizon Therapeutics, Thomson Locations: Manhattan, New York City , New York, U.S, COVID, Bengaluru

☆ FTC chair defends tenure as lawmakers battle over consumer agency's impact
▼ + stars: | 2023-07-13 | by ( Diane Bartz | David Shepardson | ) www.reuters.com time to read: +3 min

Representative Kevin Kiley, Republican from California, asked Khan about the cases that the agency had lost. “We fight hard when we believe there was a law violation, and unfortunately things don’t always go our way,” responded Khan. The agency also lost a fight to stop Facebook parent Meta Platforms from buying VR content maker Within Unlimited. Democrats on the committee sought to defend Khan, occasionally joined by Republicans on the panel including Rep. Ken Buck. Rep. Scott Fitzgerald, a Republican, however, worried about investors in small businesses losing their exit strategies.

Persons: Lina Khan, Lina M, Khan, Bill Nelson, Graeme Jennings, Activision Blizzard, Kevin Kiley, “, don’t, ”, ” Kiley, ” Khan, Darrell Issa, Trump, Ken Buck, Michael Kikukawa, Scott Fitzgerald, “ you’re, you’re, Black Knight, Jim Jordan, Elon, Jerry Nadler, Nadler Organizations: WASHINGTON, U.S . Federal Trade Commission, Republican, Commerce, Science, NASA, Capitol, Committee, Microsoft, “, Activision, Facebook, Republicans, White House Press, Rep, Black, Horizon Therapeutics, Twitter, FTC, Democrat Locations: Washington , U.S, California, U.S

[1/2] The sun sets behind the U.S. Capitol dome in Washington, U.S., on midterm election day, November 6, 2018. It was not the first loss for the agency under Khan. In addition, an internal FTC judge ruled for Illumina's (ILMN.O) purchase of Grail (GRAL.O). Lawmakers are also expected to bring up the committee's requests for documents regarding the agency's review of billionaire Elon Musk's purchase of Twitter. Conservatives have accused social media companies, including Twitter before it was acquired by Musk, of seeking to stifle conservative voices.

Persons: James Lawler Duggan, Lina Khan, Jim Jordan, Trump, Black Knight, Amgen's, Elon Musk's, Diane Bartz, Matthew Lewis Organizations: U.S, Capitol, REUTERS, WASHINGTON, U.S . Federal Trade Commission, Republican, Committee, FTC, Microsoft, Activision, Khan, Facebook, Illumina's, Black, Horizon Therapeutics, Twitter, Musk, Thomson Locations: Washington , U.S, Washington

☆ Biden names two Republican nominees for FTC commissioner, White House says
▼ + stars: | 2023-07-03 | by ( ) www.reuters.com time to read: +2 min

WASHINGTON, July 3 (Reuters) - U.S. President Joe Biden has nominated Virginia Solicitor General Andrew Ferguson and Utah Solicitor General Melissa Holyoak to fill Republican slots at the Federal Trade Commission, the White House said Monday. The FTC "operates best at full strength, and I will look forward to working with them," she said. A native of Virginia, Ferguson has an undergraduate degree from the University of Virginia and a law degree from the University of Virginia School of Law. Holyoak is the Utah Solicitor General with the Utah Attorney General's Office. Her undergraduate degree is from the University of Utah, as is her law degree.

Persons: Joe Biden, Andrew Ferguson, Melissa Holyoak, Lina Khan, Khan, Ferguson, Holyoak, Biden, Donald Trump's, Mitch McConnell, Lindsey Graham, Chuck Grassley, Myers, Amgen's, Black Knight, Diane Bartz, Kanishka Singh, Eric Beech, David Gregorio Our Organizations: Federal Trade Commission, U.S, Senate, FTC, Democratic, Facebook, Amazon.com, Albertsons, Senate Republican, University of Virginia, University of Virginia School of Law, Utah Attorney General's, Myers LLP, Hamilton Lincoln Law Institute, Competitive Enterprise Institute, Center for, University of Utah, Activision, Horizon Therapeutics, Black, Thomson Locations: Utah, Virginia

NEW YORK/LONDON, June 30 (Reuters) - Global mergers and acquisitions (M&A) activity fell 36% year-on-year in the second quarter, but investment bankers and lawyers expressed optimism that the stock market's recovery will gradually restore chief executives' dealmaking confidence. "Global uncertainty is what is impacting M&A most - it just makes people uncomfortable. It's easier to say, I'll pass on a deal - nobody gets fired for passing on a deal. M&A volumes in the United States declined by 30% to $318.4 billion, while Europe and Asia Pacific volumes shrank 49% and 24% respectively. Not a single so-called mega-deal, which typically refers to transactions worth over $25 billion, was signed during the quarter.

Persons: Michael Aiello, Weil, Raymond McGuire, Steve Baronoff, Bunge, John Collins, Morgan Stanley, there’ll, Ethan Klingsberg, Deringer, Manolo Falco, Scott Miller, Sullivan, Cromwell, Howard Ellin, Flom, Dwayne Lysaght, Eric Schiele, Kirkland, Ellis, Anirban Sen, Andres Gonzalez, Stephen Coates Organizations: Manges LLP, Lazard Ltd, Bank of America, Reuters Graphics Reuters, Magellan Midstream Partners, Viterra Ltd, Carrier Global, Investment, Citigroup Inc, JPMorgan Chase, Antitrust, U.S . Federal Trade Commission, Horizon Therapeutics, Thomson Locations: United, Europe, Asia, Skadden, Slate, New York, London

☆ California, other states join FTC bid to block Amgen deal
▼ + stars: | 2023-06-22 | by ( David Shepardson | ) www.reuters.com time to read: +2 min

WASHINGTON, June 22 (Reuters) - The states of California, New York, Illinois, Minnesota, Washington and Wisconsin have joined a Federal Trade Commission (FTC) lawsuit to stop Amgen's (AMGN.O) $27.8 billion deal to buy Horizon Therapeutics (HZNP.O), according to a court filing on Thursday. Washington Attorney General Bob Ferguson said his state had joined the lawsuit because "monopolies harm consumers" and the merger could allow Amgen to "dominate" prescription drug markets. The FTC acquisition marks a change for the agency, which previously had typically flagged therapeutic overlaps in companies and waved deals through after requiring one of the medicines to be divested. Amgen said in a statement last month it was disappointed by the FTC decision and it believed it had "overwhelmingly demonstrated" that the deal had no legitimate competitive issues. The last major pharmaceutical deal approved by the FTC was AstraZeneca's (AZN.L) $39 billion acquisition of Alexion Pharma in April 2021, about two months before FTC Chair Lina Khan was appointed by the Biden administration.

Persons: Bob Ferguson, Rob Bonta, Amgen, Lina Khan, Biden, David Shepardson, Jamie Freed Organizations: Federal Trade Commission, Horizon Therapeutics, . Washington, FTC, Horizon, Alexion Pharma, Thomson Locations: California , New York , Illinois, Minnesota, Washington, Wisconsin, California

☆ 'Uber crowded' trades from professional investors are crushing the market, Jefferies says
▼ + stars: | 2023-06-01 | by ( Yun Li | ) www.cnbc.com time to read: +1 min

Professional investors' high-conviction bets have paid off this year, significantly beating the S & P 500 , according to Jefferies. These stocks have led the market this year amid Wall Street's obsession with what investors consider safe earnings, and all things tied to artificial intelligence. Microsoft is another red-hot AI bet as the company recently expanded a multiyear, multibillion-dollar investment in ChatGPT maker OpenAI, marking the third phase of their partnership. Microsoft shares are up about 39% in 2023. The company recently increased its projections for income and net new recurring revenue from its Digital Media business for the full year.

Persons: Jefferies, Bill Ackman, Stanley Druckenmiller, Dan Loeb Organizations: Big Tech, Microsoft, Meta, Google, Nvidia, Software, Adobe, Digital Media, Horizon Therapeutics

☆ Hedge funds piled into these stocks in the first quarter
▼ + stars: | 2023-05-22 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

The Wall Street firm analyzed hundreds of 13F filings last week to find the most popular stocks hedge funds picked up over the volatile quarter. Hedge funds piled into Victoria's Secret in the first quarter, buying the dip in the lingerie retailer, which has seen its shares fall 29% this year. Hedge funds also increased their ownership in financial names Western Alliance and Western Union last quarter. To be sure, it's possible that some of the hedge funds were covering their short bets in this position. A number of biotech names were also high-conviction bets for hedge funds, including Syneos Health , Horizon Therapeutics and Ginkgo Bioworks.

May 18 (Reuters) - Amgen Inc (AMGN.O) has agreed not to quickly close on its $27.8 billion acquisition of Horizon Therapeutics (HZNP.O) after the U.S. Federal Trade Commission (FTC) filed suit to block the deal. Absent an agreement, Amgen could have sought to close the deal as early as Monday. Under the order, Amgen and Horizon will not close their transaction until the earlier of Sept. 15, or the second business day after the court rules on the FTC's request for a preliminary injunction. Amgen said it had made an offer to the FTC in the hope of resolving the issue. "We committed that we would not bundle the Horizon products raised as issues," Amgen said in a statement.

That would appear to contradict the FTC's practice of preventing companies from using market power to push up prices. The FTC lawsuit spurred concern among investors who had brushed off the antitrust risk in Amgen's deal because of its limited business overlap with Horizon. "Our complaint is firmly rooted in longstanding antitrust law and we look forward to making our argument in court," an FTC spokesperson said. AMGEN OFFERS REMEDYAmgen said on Tuesday it had made an offer to the FTC in hopes of resolving the issue. "These are valid concerns that FTC has raised but what a court will do about it is uncertain," he said.

☆ Horizon Therapeutics says Amgen deal could close earlier than planned if FTC fails to block it
▼ + stars: | 2023-05-18 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Horizon Therapeutics expects its $27.8 billion sale to Amgen to close as early as the end of the third quarter, earlier than previously planned — if the Federal Trade Commission's attempt to block the deal fails — according to a document filed Thursday with the Securities and Exchange Commission. The FTC on Tuesday filed a lawsuit in Illinois federal court seeking to halt the acquisition, arguing it would "stifle competition" in the pharmaceutical industry. Horizon's estimate is earlier than when the companies and Wall Street analysts were initially expecting the deal to close after the FTC sued. If completed, the deal would give Amgen access to Horizon's blockbuster thyroid eye disease drug, Tepezza, and its gout medicine, Krystexxa. The agency said the deal would allow Amgen to "entrench the monopoly positions" of those two fast-growing drugs from Horizon.

☆ Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
▼ + stars: | 2023-05-17 | by ( David Carnevali | ) www.reuters.com time to read: +4 min

Even shares of drug companies that do not have pending deals but are seen by analysts and investors as potential acquisition targets were hit. FTC officials did not respond to a request for comment on whether they planned to challenge any other pharmaceutical acquisitions. "We could see similar challenges to the Pfizer/Seagen deal" BMO analysts wrote in a note, arguing that the FTC could target other major drug companies with the resources to engage in bundling. UNDER THE RADARConversely, investors and analysts are hoping that smaller pharmaceutical acquisitions will continue to fly under the radar of regulators. Reporting by David Carnevali in New York; Editing by Greg Roumeliotis and Jamie FreedOur Standards: The Thomson Reuters Trust Principles.

☆ Wall Street closes lower after Home Depot outlook, US retail sales
▼ + stars: | 2023-05-17 | by ( Chuck Mikolajczak | ) www.reuters.com time to read: +4 min

The Commerce Department reported retail sales rose 0.4% in April, short of the estimate for an increase of 0.8%. That slowing along with recent negotiations over the U.S. debt ceiling has focused attention on when the central bank will pause hiking, or cut interest rates. While the market is currently pricing in a rate cut by the end of the year, recent comments from Fed officials suggested they are not ready to cut rates soon. Cleveland Fed President Loretta Mester said she does not think the central bank can hold interest rates steady yet. (This story has been corrected to say 'a rate cut,' instead of 'a rate hike,' in paragraph 8)Reporting by Shreyashi Sanyal in Bengaluru; Editing by Maju SamuelOur Standards: The Thomson Reuters Trust Principles.

☆ S&P 500, Dow fall, dragged by Home Depot outlook, US retail sales
▼ + stars: | 2023-05-16 | by ( Chuck Mikolajczak | ) www.reuters.com time to read: +4 min

Home Depot (HD.N) shed 1.73%, the biggest drag on the Dow Industrials and among the heaviest weights on the S&P 500 after the home improvement retailer cut its annual sales forecast and projected a steeper-than-expected decline in profit. The Commerce Department reported retail sales rose 0.4% in April, short of the estimate for an increase of 0.8%. That slowing along with recent negotiations over the U.S. debt ceiling has focused attention on when the central bank will pause hiking, or cut interest rates. Cleveland Fed President Loretta Mester said she does not think the central bank can hold interest rates steady yet. The S&P 500 posted 10 new 52-week highs and 12 new lows; the Nasdaq Composite recorded 42 new highs and 163 new lows.

The Commerce Department reported retail sales rose 0.4% in April, at half the pace against an expected increase of 0.8%. "The retail sales data has been positive in several months, but it's still weak," said Jamie Cox, managing partner at Harris Financial Group. You are probably seeing the end of the decline in retail sales, but it's not going to be a smooth ride from here." Dow Jones Industrial Average (.DJI) component Home Depot (HD.N) shed 1.4%, hitting its lowest level in over six months after the company lowered its annual sales forecast. Shares of Capital One Financial Corp (COF.N) jumped 2.4%, rising the most on the S&P 500, after Berkshire Hathaway Inc (BRKa.N) on Monday disclosed it has begun investing in the consumer lender.

☆ US FTC sues to block Amgen's $27.8 bln deal for Horizon Therapeutics
▼ + stars: | 2023-05-16 | by ( ) www.reuters.com time to read: +1 min

WASHINGTON, May 16 (Reuters) - The U.S. Federal Trade Commission said on Tuesday it would sue to stop Amgen Inc's (AMGN.O) $27.8 billion deal to buy Horizon Therapeutics Plc (HZNP.O). The agency said it was opposing the deal because it would give Amgen "monopoly positions" for medicines used to treat thyroid eye disease and chronic refractory gout. The deal, which was announced in December 2022, would give Amgen two fast-growing drugs, the thyroid eye disease treatment Tepezza and gout treatment Krystexxa. Other key drugs in Amgen's product portfolio, such as psoriasis therapy Otezla, face the loss of patent protections over the next few years. It is unusual for the agency to sue to stop a pharmaceutical deal.

☆ FTC sues to block Amgen's $27.8 bln deal for Horizon Therapeutics -statement
▼ + stars: | 2023-05-16 | by ( ) www.reuters.com time to read: 1 min

WASHINGTON, May 16 (Reuters) - The U.S. Federal Trade Commission said on Tuesday that it would sue to stop Amgen Inc's (AMGN.O) $27.8 billion deal to buy Horizon Therapeutics Plc (HZNP.O). The deal, which was announced in December 2022, would give Amgen two fast-growing drugs, the thyroid eye disease treatment Tepezza and gout treatment Krystexxa. Amgen hopes they can act as a bulwark against competition for its blockbuster arthritis drug Enbrel. Furthermore, other key drugs in its portfolio, such as psoriasis therapy Otezla, face loss of patents over the next few years. Reporting by Diane Bartz; editing by Tim AhmannOur Standards: The Thomson Reuters Trust Principles.

The Commerce Department reported retail sales rose 0.4% in April, at half the pace against an expected increase of 0.8%. "The retail sales data has been positive in several months, but it's still weak," said Jamie Cox, managing partner at Harris Financial Group. You are probably seeing the end of the decline in retail sales, but it's not going to be a smooth ride from here." "There is little chance we will see a resolution to the U.S. debt ceiling issue today," said Ipek Ozkardeskaya, senior analyst at Swissquote Bank. "The negotiations will likely remain tight as Republicans ask decent spending cuts to accept a debt ceiling relief, while Biden is not willing to compromise on spending into the election year."

☆ FTC Moves to Block Amgen’s $27.8 Billion Deal for Horizon Therapeutics
▼ + stars: | 2023-05-16 | by ( Dave Michaels | Joseph Walker | ) www.wsj.com time to read: 1 min

Amgen said it was disappointed by the FTC’s decision but doesn’t believe a merger presents any competitive issues. Photo: Eric Thayer/Bloomberg NewsThe Federal Trade Commission said Tuesday it is seeking to block Amgen ’s $27.8 billion acquisition of Horizon Therapeutics , in a new effort by antitrust enforcers to prevent a merger of pharmaceutical companies. The FTC filed a lawsuit in federal court seeking an injunction that would prevent the deal from closing. A federal judge would need to approve the injunction. That is part of a two-step legal process the agency typically uses to prevent mergers it believes are illegal.

☆ FTC’s Amgen Activism Will Spare These Biotechs
▼ + stars: | 2023-05-16 | by ( David Wainer | ) www.wsj.com time to read: 1 min

The Federal Trade Commission’s effort to block Amgen’s acquisition of Horizon Therapeutics is putting a damper on the recent biotech stocks rally. Photo: Eric Lee for The Wall Street JournalBiotech stocks were on a tear in recent weeks, rebounding from the sector’s horrid performance of the last two years. The Federal Trade Commission’s effort to block Amgen ’s acquisition of Horizon Therapeutics is putting a damper on that rally. The SPDR S&P Biotech exchange-traded fund was down 3.4% on Tuesday morning, with Horizon plunging 18%. Seagen , which agreed to sell itself to Pfizer for $43 billion in March, was down 6%.

☆ FTC’s Amgen Activism Will Spare Smaller Biotechs
▼ + stars: | 2023-05-16 | by ( David Wainer | ) www.wsj.com time to read: 1 min

The Federal Trade Commission’s effort to block Amgen’s acquisition of Horizon Therapeutics is putting a damper on the recent biotech stocks rally. Photo: Eric Lee for The Wall Street JournalBiotech stocks were on a tear in recent weeks, rebounding from the sector’s horrid performance of the last two years. The euphoria was based on the premise that pharma companies would keep paying massive premiums for biotech companies because their own blockbuster drugs were going off patent.

The main indexes started the week with modest gains as trading was range-bound amid a wrangling in Washington between the White House and Republicans. "There is little chance we will see a resolution to the U.S. debt ceiling issue today," said Ipek Ozkardeskaya, senior analyst at Swissquote Bank. Shares of rival Lowe's Companies Inc (LOW.N) fell 3.2%, while retail giant Walmart Inc (WMT.N) slipped 0.4%. Focus will also be on economic data, with retail sales expected to increase by 0.8% in April after falling 0.6% in the month before. ET, Dow e-minis were down 80 points, or 0.24%, S&P 500 e-minis were down 3 points, or 0.07%, and Nasdaq 100 e-minis were up 5.25 points, or 0.04%.

☆ FTC Poised to Block Amgen’s $27.8 Billion Deal for Horizon Therapeutics
▼ + stars: | 2023-05-16 | by ( Dave Michaels | Joseph Walker | ) www.wsj.com time to read: 1 min

Amgen said it isn’t aware of any decision by the Federal Trade Commission. Photo: Eric Thayer/Bloomberg NewsThe Federal Trade Commission is preparing to block Amgen ’s acquisition of Horizon Therapeutics , a person familiar with the matter said, marking a new effort by antitrust enforcers to prevent a merger of pharmaceutical companies. The FTC is preparing to seek an injunction in federal court that would prevent the deal from closing, according to the person familiar with the matter. A federal judge would need to approve the injunction. That is part of a two-step legal process the agency typically uses to prevent mergers it believes are illegal.

☆ FTC to block Amgen's $27.8 billion deal for Horizon Therapeutics - source
▼ + stars: | 2023-05-16 | by ( ) www.reuters.com time to read: +2 min

May 15 (Reuters) - The U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc's (AMGN.O) $27.8 billion deal to buy Horizon Therapeutics PLC (HZNP.O), a person familiar with the matter told Reuters. Amgen struck a deal last year to buy Horizon to strengthen its rare diseases drugs portfolio. Senator Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the FTC earlier this year expressing her concerns about pharmaceutical deals including the Amgen purchase of Horizon. The Democratic Senator said both Amgen and Horizon Therapeutics "have engaged in brazen price increases," including on Amgen's Enbrel for arthritis and Horizon’s Krystexxa, a gout medication. The deal would give Amgen two fast-growing drugs, the thyroid eye disease treatment Tepezza and Krystexxa.

Search resuls for: "Horizon Therapeutics"

25 mentions found